The role of galectin‐3 in heart failure and cardiovascular disease

Summary Galectin‐3, a β‐galactoside‐binding lectin, is a new important player in the progression of heart failure (HF) and is also linked to poor outcome in patients with cardiovascular disease. Genetic or pharmacological inhibition of galectin‐3 slows down the progression of myocardial inflammation...

Full description

Saved in:
Bibliographic Details
Published inClinical and experimental pharmacology & physiology Vol. 46; no. 3; pp. 197 - 203
Main Authors Zhong, Xiao, Qian, Xiaoqian, Chen, Guangping, Song, Xiang
Format Journal Article
LanguageEnglish
Published Australia Wiley Subscription Services, Inc 01.03.2019
Subjects
aldosterone
angiotenin II
Animals
Cardiovascular disease
Cardiovascular diseases
Collagen
Congestive heart failure
Coronary artery disease
Fibrosis
Galectin 3 - metabolism
galectin‐3
Heart failure
Heart Failure - diagnosis
Heart Failure - metabolism
Heart Failure - pathology
Heart Failure - therapy
Humans
Pharmacology
Risk Assessment
angiotenin II
cardiovascular disease
fibrosis
galectin-3
aldosterone
Online AccessGet full text

Cover

More Information
Summary:Summary Galectin‐3, a β‐galactoside‐binding lectin, is a new important player in the progression of heart failure (HF) and is also linked to poor outcome in patients with cardiovascular disease. Genetic or pharmacological inhibition of galectin‐3 slows down the progression of myocardial inflammation, reduces collagen production, attenuates cardiac remodelling, and ameliorates cardiac function. In this review, we summarize recent progress in research on galectin‐3 as a regulatory molecule involved in cardiovascular fibrosis in HF and its potential role in the diagnosis, risk assessment and treatment of cardiovascular diseases.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
ObjectType-Review-3
content type line 23
ISSN:0305-1870
1440-1681
1440-1681
DOI:10.1111/1440-1681.13048